Oslo, December 9, 2025 - Navamedic ASA Introduces Flexilev[®] in OraFID[®]: Enhancing Parkinson's Care with Simplified and Precise Dosing for Personalized Treatment

09 Dec 2025 13:00 CET

Navamedic ASA is excited to announce the launch of Flexilev[®] in OraFID[®], a
novel, single-use dosing dispenser specifically designed to deliver precise and
personalized Parkinson's treatment in a user-friendly format. The product will
be available for prescription at pharmacies late December/early January.

As Parkinson's disease advances, patients frequently experience variations in
motor abilities throughout the day. For those facing reduced efficacy towards
the end of the dosing interval (dose gaps) the OraFID[®] dispenser provides an
enhanced opportunity to fine tune levodopa treatment.
This combination of drug and device allows for dosing adjustments to address
each patient's specific requirements at any given time, thereby minimizing the
risk of under- or overdosing and associated side effects. It offers a simplified
approach to achieving precise medication delivery.

Kathrine Gamborg Andreassen, CEO of Navamedic ASA, states: "This concept
reflects our unwavering commitment to be a proud contributor to public health by
improving patient outcomes through personalized treatment solutions, utilizing
minitablets."

Navamedic ASA will oversee the launch and marketing in Sweden, Norway and
Denmark. Orion Corporation ("Orion") has been granted exclusive rights to
market, distribute, and sell the product across 27 European countries. As the
marketing authorization (MA) holder within their designated territory, Orion
will assume all associated rights and responsibilities.

For further information, please contact:

Kathrine Gamborg Andreassen

CEO,
Navamedic

Mobile: +47 951
78 680

E-mail: kathrine@navamedic.com

About Navamedic ASA
Navamedic ASA is a leading company in the pharmaceutical industry, committed to
delivering innovative healthcare solutions to improve patient outcomes. With a
strong presence in Scandinavia and partnerships across Europe, Navamedic
continues to expand its portfolio and enhance its impact in the healthcare
sector.
About Orion Corporation
Orion is a globally operating Nordic pharmaceutical company - a builder of well
-being for over a hundred years. We develop, manufacture and market human and
veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an
extensive portfolio of proprietary and generic medicines and consumer health
products. The core therapy areas of our pharmaceutical R&D are oncology and
pain. Proprietary products developed by Orion are used to treat cancer,
neurological diseases and respiratory diseases, among others. In 2024 Orion's
net sales amounted to EUR 1,542 million and the company employed about 3,700
professionals worldwide, dedicated to building well-being. Orion's A and B
shares are listed on Nasdaq Helsinki.

More information:
Access the news on Oslo Bors NewsWeb site